Sotera Health Co SHC revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Sotera Health Co reported revenue across 3 business segments; the largest, Sterigenics, was $756M, 65.0% of the filed sum (+8.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Sterigenics$756M65.0%+8.3% yoy
- Nelson Labs$220M18.9%-3.9% yoy
- Nordion$188M16.1%+8.2% yoy
Members sum to the consolidated $1.16B for this period.
- Service$996M85.6%+5.7% yoy
- Product$168M14.4%+5.8% yoy
Members sum to the consolidated $1.16B for this period.
- United States$630M54.1%+2.1% yoy
- Europe$232M20.0%+18.5% yoy
- Canada$222M19.1%+6.3% yoy
- Other Geographical Areas$79.9M6.9%+1.4% yoy
Members sum to the consolidated $1.16B for this period.
- Sterigenics$186M66.5%+9.7% yoy
- Nelson Labs$51.9M18.5%-0.7% yoy
- Nordion$42M15.0%+29.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.